Accordingly, molecules involved in necroptotic signaling, such as receptor-interacting serine/threonine-protein kinase 3 (<i>RIPK3</i>) and mixed lineage kinase-like (<i>MLKL</i>) have been found to stimulate anticancer immune responses in mouse models of chemotherapy. mRNAs encoding prominent pro-necrotic gene products (<i>RIPK1</i>, <i>RIPK3</i>, <i>MLKL</i>, <i>PGAM5</i> and <i>DFNA5</i>) were correlated with immune-related metagenes in several cancer types (breast, colorectal, lung, ovary, melanoma), revealing the strongest associations in breast cancer.
Gene expression analyses of breast cancers expressing high levels of Myc indicated that low miR-206 expression and high MAP3K13 expression correlated with poor patient survival.